# NovoCure Ltd. (NVCR)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $1.97B  
**Price:** $17.71 (+6.37%)

> Novocure Ltd. is a global oncology company that develops and commercializes Tumor Treating Fields (TTFields), an innovative, non-invasive cancer therapy using alternating electric fields tuned to specific frequencies to disrupt cancer cell division while sparing healthy tissue. Its commercialized products, including Optune Gio, Optune Lua, and Optune Pax, are approved in certain countries for treating adult patients with glioblastoma, pancreatic cancer, non-small cell lung cancer, and malignant pleural mesothelioma. Novocure Ltd. focuses on extending survival in aggressive solid tumor cancers through this proprietary platform, which targets tumors without many traditional chemotherapy side effects. The company manufactures and distributes these wearable devices internationally, with operations spanning North America, Europe, the Middle East, Asia, Germany, and Japan. It conducts ongoing phase 2 and phase 3 clinical trials exploring TTFields in glioblastoma, non-small cell lung cancer, and pancreatic cancer, alongside a pipeline including products like Trident, Lunar-2, Panova-3, and Metis. Founded in 2000 and headquartered in St. Helier, Jersey, Novocure Ltd. plays a significant role in advancing novel oncology treatments.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $655M | $488M | -$154M | -$136M | — |
| 2024 | $605M | $468M | -$170M | -$169M | — |
| 2023 | $509M | $381M | -$233M | -$207M | — |
| 2022 | $538M | $423M | -$90M | -$93M | — |
| 2021 | $535M | $420M | -$44M | -$58M | — |
| 2020 | $494M | $388M | $30M | $20M | — |
| 2019 | $351M | $263M | -$914,000 | -$7M | — |
| 2018 | $248M | $168M | -$34M | -$64M | — |
| 2017 | $177M | $121M | -$39M | -$62M | — |
| 2016 | $83M | $37M | -$115M | -$132M | — |
| 2015 | $33M | $12M | -$104M | -$112M | — |
| 2014 | $15M | $5M | -$80M | -$81M | — |
| 2013 | $10M | $3M | -$64M | -$77M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $804M | $464M | $340M | $94M | $195M |
| 2024 | $1.24B | $881M | $360M | $164M | $97M |
| 2023 | $1.15B | $784M | $362M | $241M | $569M |
| 2022 | $1.19B | $750M | $441M | $115M | $566M |
| 2021 | $1.14B | $729M | $410M | $209M | $562M |
| 2020 | $1.05B | $575M | $477M | $235M | $430M |
| 2019 | $479M | $262M | $218M | $177M | $149M |
| 2018 | $340M | $228M | $112M | $141M | $149M |
| 2017 | $265M | $152M | $114M | $79M | $97M |
| 2016 | $282M | $140M | $142M | $100M | $96M |
| 2015 | $307M | $57M | $251M | $119M | $23M |
| 2014 | $118M | $20M | $98M | $58M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$49M | $27M | -$76M |
| 2024 | -$26M | $43M | -$69M |
| 2023 | -$73M | $27M | -$100M |
| 2022 | $31M | $21M | $9M |
| 2021 | $83M | $24M | $59M |
| 2020 | $99M | $15M | $84M |
| 2019 | $27M | $10M | $16M |
| 2018 | -$2M | $7M | -$9M |
| 2017 | -$33M | $7M | -$41M |
| 2016 | -$108M | $6M | -$113M |

Source: [CompaniesByCap](https://companiesbycap.com/company/NVCR)